Fortress Biotech, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
Fortress Biotech, Inc. (FBIO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet · last filed 2026-08-13
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2026-06-30 was $0.00.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2026-03-31 was $0.00.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for fiscal 2020 was -$1.22M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | |||
| 2020-12-31 | -$1.22M 10-K/A · filed 2021-04-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |